MaltSci 麦伴科研

Appearance

Popular Reports / psychiatry

This report is written by MaltSci based on the latest literature and research findings

How does neurostimulation treat psychiatric disorders? ​

Abstract ​

Psychiatric disorders represent a significant public health challenge, affecting millions globally and leading to substantial disability and morbidity. Traditional treatment approaches, primarily pharmacological and psychotherapeutic, have limitations, leaving many patients inadequately treated or with adverse effects. This has prompted interest in alternative modalities, particularly neurostimulation techniques, which aim to modulate neural activity and address the neurobiological underpinnings of psychiatric disorders. This report provides an overview of key neurostimulation techniques, including Transcranial Magnetic Stimulation (TMS), Deep Brain Stimulation (DBS), and Electroconvulsive Therapy (ECT), examining their mechanisms of action, clinical applications, and efficacy. TMS is highlighted for its non-invasive ability to influence cortical excitability and neuroplasticity, demonstrating effectiveness in major depressive disorder and anxiety disorders. DBS, though invasive, shows promise in treatment-resistant cases of obsessive-compulsive disorder and depression by modulating specific brain circuits. ECT remains a critical intervention for severe psychiatric conditions, particularly when rapid response is necessary. Despite the progress made, the field faces challenges, including gaps in understanding the precise mechanisms of these therapies, patient selection, treatment protocols, and ethical considerations surrounding device use. Ongoing research is essential to optimize neurostimulation techniques, explore combination therapies, and address the ethical implications of these interventions. By synthesizing recent findings and clinical applications, this report aims to provide a comprehensive overview of how neurostimulation can transform the treatment landscape for psychiatric disorders, paving the way for more effective and personalized therapeutic strategies.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Neurostimulation Techniques
    • 2.1 Transcranial Magnetic Stimulation (TMS)
    • 2.2 Deep Brain Stimulation (DBS)
    • 2.3 Electroconvulsive Therapy (ECT)
  • 3 Mechanisms of Action
    • 3.1 Modulation of Neural Circuits
    • 3.2 Neurotransmitter Systems Involved
    • 3.3 Neuroplasticity and Long-term Effects
  • 4 Applications in Psychiatric Disorders
    • 4.1 Treatment of Major Depressive Disorder
    • 4.2 Anxiety Disorders
    • 4.3 Obsessive-Compulsive Disorder (OCD)
  • 5 Efficacy and Safety Considerations
    • 5.1 Clinical Outcomes and Effectiveness
    • 5.2 Side Effects and Risks
    • 5.3 Patient Acceptance and Adherence
  • 6 Future Directions and Challenges
    • 6.1 Innovations in Neurostimulation Technology
    • 6.2 Research Gaps and Opportunities
    • 6.3 Ethical Considerations
  • 7 Conclusion

1 Introduction ​

Psychiatric disorders represent a significant public health challenge, affecting millions of individuals worldwide and leading to substantial disability, morbidity, and mortality. Traditional treatment approaches, primarily pharmacological and psychotherapeutic interventions, have proven effective for some patients; however, a considerable proportion remains inadequately treated or experiences adverse effects [1][2]. The limitations of these conventional therapies have sparked interest in alternative treatment modalities, particularly neurostimulation techniques. Neurostimulation encompasses a range of methods designed to modulate neural activity, offering promising therapeutic avenues for conditions such as depression, anxiety disorders, and obsessive-compulsive disorder (OCD) [3][4].

The significance of neurostimulation in psychiatry is underscored by its potential to address the neurobiological underpinnings of psychiatric disorders. Recent advancements in our understanding of brain circuitry and the neural networks involved in mood regulation have led to the development of targeted neuromodulation therapies [5]. These approaches aim to restore normal functioning in dysregulated neural circuits, thereby alleviating symptoms and improving patient outcomes. Techniques such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and electroconvulsive therapy (ECT) have emerged as critical tools in this evolving therapeutic landscape [6][7].

Current research highlights the efficacy of neurostimulation techniques, particularly in treatment-resistant cases where traditional therapies have failed [2]. For instance, TMS has been shown to provide significant symptom relief in patients with major depressive disorder, while DBS has demonstrated promise in treating OCD [3][4]. Furthermore, emerging evidence suggests that combining neurostimulation with cognitive interventions may enhance therapeutic outcomes by optimizing neural activity [8].

Despite the progress made, the field of neurostimulation for psychiatric disorders is still in its infancy. There remain significant gaps in our understanding of the precise mechanisms by which these therapies exert their effects, as well as challenges related to patient selection, treatment protocols, and long-term safety [9]. Additionally, ethical considerations surrounding the use of implanted devices and the implications of closed-loop neurostimulation systems necessitate careful scrutiny as the field advances [5].

This report is organized as follows: Section 2 provides an overview of the primary neurostimulation techniques currently in use, including TMS, DBS, and ECT. Section 3 delves into the mechanisms of action, focusing on the modulation of neural circuits, neurotransmitter systems involved, and the role of neuroplasticity in long-term treatment effects. Section 4 examines the applications of neurostimulation in major psychiatric disorders, while Section 5 evaluates the efficacy and safety considerations associated with these interventions. Finally, Section 6 discusses future directions and challenges in the field, highlighting innovations in neurostimulation technology, research gaps, and ethical considerations. By synthesizing recent findings and clinical applications, this report aims to provide a comprehensive overview of how neurostimulation can transform the treatment landscape for psychiatric disorders, paving the way for more effective and personalized therapeutic strategies.

2 Overview of Neurostimulation Techniques ​

2.1 Transcranial Magnetic Stimulation (TMS) ​

Transcranial Magnetic Stimulation (TMS) is a non-invasive neurostimulation technique that has gained significant attention in the treatment of various psychiatric disorders. This technique employs magnetic fields to induce electrical currents in specific areas of the brain, thereby modulating neuronal activity. TMS is particularly noteworthy for its ability to influence cortical excitability and facilitate neuroplasticity, which are critical factors in addressing psychiatric conditions.

The mechanism of TMS involves the application of alternating magnetic fields that generate electric currents in the cortical tissue. This process allows for targeted stimulation of brain regions associated with mood regulation, cognition, and behavior. Repetitive TMS (rTMS), which involves the delivery of multiple magnetic pulses, has been shown to enhance neuronal excitability and promote changes in synaptic plasticity, which are vital for therapeutic outcomes in psychiatric disorders such as depression, anxiety, and schizophrenia [10].

Numerous studies have highlighted the efficacy of rTMS in treating major depressive disorder, with meta-analyses indicating that both low-frequency and high-frequency rTMS can produce antidepressant effects. However, the variability in response rates and the durability of these effects remain subjects of ongoing research [11]. The specific targeting of cortical areas through TMS has allowed clinicians to tailor interventions based on individual patient profiles, thereby improving treatment personalization [12].

TMS has also been explored for its applications beyond depression, including anxiety disorders, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and schizophrenia. For instance, TMS has demonstrated potential in alleviating auditory hallucinations in schizophrenia when applied to the auditory cortex [13]. Furthermore, studies combining TMS with electroencephalography (EEG) have provided insights into the underlying neural mechanisms, enhancing our understanding of the pathophysiology of these disorders [12].

The role of neurophysiological biomarkers in predicting treatment response has emerged as a promising area of investigation. These biomarkers, derived from TMS-EEG studies, may offer insights into individual variability in treatment outcomes, thus guiding clinicians in optimizing TMS protocols [10]. Moreover, the integration of advanced imaging techniques, such as functional near-infrared spectroscopy, may further refine TMS application by enabling real-time monitoring of brain activity during stimulation [14].

In conclusion, TMS represents a significant advancement in the neurostimulation landscape for treating psychiatric disorders. Its ability to non-invasively modulate brain activity, combined with ongoing research into personalized treatment approaches and neurophysiological markers, positions TMS as a critical tool in modern psychiatric care. Future studies are essential to elucidate the optimal parameters for TMS application and to establish its efficacy across a broader spectrum of psychiatric conditions.

2.2 Deep Brain Stimulation (DBS) ​

Neurostimulation, particularly through the technique of Deep Brain Stimulation (DBS), has emerged as a promising intervention for various psychiatric disorders that are resistant to conventional treatments. DBS involves the implantation of electrodes in specific brain regions, delivering electrical impulses that modulate neural activity. This method has shown efficacy in treating movement disorders and is increasingly being explored for psychiatric applications.

DBS has been FDA-approved for conditions such as Parkinson's disease and essential tremor, and it has received humanitarian device exemptions for disorders like dystonia and obsessive-compulsive disorder (OCD) [15]. The therapeutic mechanisms of DBS remain a subject of ongoing research, but it is generally believed to exert its effects by altering abnormal neural circuitry associated with these disorders [16].

In the realm of psychiatric disorders, DBS has been utilized experimentally for conditions including OCD, treatment-resistant depression, Tourette syndrome, and addiction [17]. Clinical studies have reported significant improvements in primary symptoms, with response rates ranging from 35% to 70% in various trials [17]. The mechanism by which DBS alleviates symptoms is thought to involve modulation of specific brain circuits that regulate mood, cognition, and behavior [18].

For example, in OCD, DBS targets areas such as the subthalamic nucleus and the ventral striatum, which are implicated in the pathophysiology of the disorder. The modulation of these areas has been associated with reduced compulsive behaviors and improved overall functioning [19]. Moreover, recent advancements in understanding the neuroanatomical models of mood and behavior regulation have paved the way for more targeted and effective applications of DBS in psychiatry [18].

Furthermore, ongoing research is exploring the potential of DBS to enhance cognitive functions beyond symptom relief. Studies have indicated that DBS could improve memory formation and recall, suggesting that it may also augment non-pathological cognitive functions [16]. This expanding scope of DBS indicates its versatility as a neuromodulatory tool, capable of addressing both pathological and non-pathological aspects of brain function.

In conclusion, DBS represents a significant advancement in the treatment of psychiatric disorders, providing hope for patients with conditions that are refractory to standard therapies. While the clinical outcomes have been promising, further methodologically rigorous studies are necessary to fully elucidate the mechanisms of action, optimize stimulation parameters, and evaluate long-term effects and safety profiles of DBS in psychiatric applications [[pmid:20221269],[pmid:21692660]].

2.3 Electroconvulsive Therapy (ECT) ​

Neurostimulation techniques, particularly Electroconvulsive Therapy (ECT), represent a critical intervention for treating severe psychiatric disorders. ECT involves the application of a carefully controlled electrical stimulus to the brain, resulting in a generalized seizure. This technique is primarily utilized for conditions such as treatment-resistant major depressive disorder, bipolar disorder, and certain forms of schizophrenia, and is noted for its rapid therapeutic effects.

ECT is administered under general anesthesia with the use of muscle relaxants, ensuring patient safety during the procedure. The modern application of ECT has evolved significantly since its inception, transitioning from its initial use in non-anesthetized patients—which often resulted in traumatic effects—to a standardized approach involving anesthesia and neuromuscular blockade. This evolution has contributed to a decrease in cognitive side effects and an overall improvement in the efficacy and safety of the treatment [20].

The therapeutic efficacy of ECT is closely linked to its neurobiological mechanisms. While the exact pathways remain partially understood, recent research highlights several critical processes. ECT is believed to modulate neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF), which plays a vital role in promoting synaptic plasticity and neuronal survival. Furthermore, ECT has been shown to influence the hypothalamic-pituitary-adrenal (HPA) axis, reduce neuroinflammation, and alter neurotransmitter systems, all contributing to its antidepressant effects [21].

Neuroimaging studies have demonstrated that ECT induces plastic changes in the hippocampus and other brain regions, suggesting that these areas are integral to the antidepressant response. Specifically, there is evidence of increased neuroplasticity in the hippocampus following ECT, which correlates with improved clinical outcomes [22]. Moreover, the physiological effects of seizures induced by ECT have been associated with alterations in brain network dynamics, particularly within thalamocortical and cerebellar circuits. These networks are thought to be active during the generalization and termination of seizures, and their interactions with corticolimbic circuits, which are dysfunctional prior to treatment, are pivotal for the therapeutic response [22].

In clinical practice, ECT is administered in a series of sessions, and patients often experience significant improvements in their depressive symptoms, with many reporting a rapid relief from their condition. For instance, a case report highlighted an elderly patient with Major Depressive Disorder who experienced musical hallucinations during ECT treatment; however, these hallucinations ceased after the completion of the therapy, and the patient showed significant improvement in her depressive symptoms [23].

Despite its effectiveness, ECT remains a subject of debate, particularly regarding its indications, optimal administration methods, and potential adverse effects. Historical concerns about its misuse in psychiatric settings have led to increased scrutiny and regulation of its application. Nevertheless, ongoing research continues to validate ECT as a vital treatment option for patients who do not respond to conventional psychiatric medications [24].

In summary, ECT serves as a powerful neurostimulation technique for treating severe psychiatric disorders through its ability to induce neurobiological changes that promote recovery. Its mechanisms involve modulation of neurotrophic factors, alterations in neurotransmitter systems, and engagement of critical brain networks, which together contribute to its therapeutic efficacy.

3 Mechanisms of Action ​

3.1 Modulation of Neural Circuits ​

Neurostimulation treats psychiatric disorders primarily through the modulation of neural circuits that regulate mood, thought, and behavior. This approach is rooted in a neural circuit paradigm, which posits that psychiatric dysfunction arises from abnormal communication within specific networks of brain regions. This understanding has led to the development of various neuromodulation therapies, including deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT), among others.

These therapies utilize electrical stimulation to induce therapeutic neuromodulation within dysfunctional neural circuitry. For instance, invasive neurostimulation systems are designed to target specific deep subcortical, cortical, spinal, cranial, and peripheral nerve structures, effectively modulating neuronal activity to provide therapeutic effects for a wide array of neuropsychiatric disorders (Edwards et al., 2017) [3]. Recent advancements in neurotechnology have allowed for the development of more precise stimulation techniques, including closed-loop systems that adjust stimulation parameters based on real-time feedback from the patient’s neural activity, thus enhancing treatment efficacy (Sellers et al., 2024) [6].

The mechanisms through which neurostimulation exerts its effects are complex and multifaceted. For example, studies have demonstrated that neuromodulation can alter neural activity across the brain, affecting both single neuron dynamics and functional connectivity within broader neural networks. This has been observed in both human and animal studies, where therapies like TMS have shown to modulate activity in key brain regions implicated in mood regulation (Fujimoto et al., 2024) [4]. Furthermore, neuromodulation therapies have been found to influence neuroinflammation, a common feature associated with mood disorders, by reducing the release of pro-inflammatory factors and thereby potentially improving mood symptoms (Guo et al., 2023) [25].

In addition to direct modulation of neural circuits, neuromodulation therapies also appear to reverse drug-evoked synaptic plasticity, which is crucial in conditions like addiction. This reversal can lead to significant behavioral changes and symptom reduction, highlighting the therapeutic potential of neuromodulation in treating a variety of psychiatric disorders (Creed, 2018) [26].

Overall, the integration of neurostimulation therapies into psychiatric treatment represents a promising avenue for addressing treatment-resistant disorders. By directly targeting and modulating the neural circuits involved in psychiatric illnesses, these therapies aim to restore normal functioning and alleviate symptoms in patients who have not responded adequately to conventional pharmacological treatments. The ongoing research into the mechanisms of action of these therapies continues to refine our understanding and application of neuromodulation in clinical settings.

3.2 Neurotransmitter Systems Involved ​

Neurostimulation therapies have emerged as significant treatment modalities for various psychiatric disorders, leveraging the principles of neuromodulation to address dysfunctions within specific neural circuits. The mechanisms of action through which neurostimulation exerts its effects are complex and multifaceted, primarily involving the modulation of neurotransmitter systems and the re-establishment of normal neural circuitry.

Neurostimulation techniques, such as deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS), work by delivering electrical stimulation to targeted brain regions. This stimulation is intended to modify the activity of neuronal circuits implicated in psychiatric conditions. For instance, these therapies have shown efficacy in treating conditions such as depression, anxiety disorders, and obsessive-compulsive disorder (OCD) by influencing neurotransmitter systems, including serotonin, dopamine, and norepinephrine, which are critical in mood regulation and emotional processing.

The interplay between these neurotransmitter systems is vital for the therapeutic outcomes of neurostimulation. For example, the serotonergic and noradrenergic systems are closely linked, and their modulation can lead to significant improvements in depressive symptoms. Research indicates that stimulation of serotonergic pathways can result in downstream noradrenergic effects, enhancing mood and cognitive function (Gorman & Sullivan, 2000) [27]. Similarly, dopamine dysregulation has been implicated in several psychiatric disorders, and neurostimulation can enhance dopaminergic activity in key brain areas, potentially alleviating symptoms associated with conditions like depression and schizophrenia (Pandurangi et al., 2012) [28].

Moreover, the efficacy of neurostimulation therapies is enhanced by advancements in neuroimaging technologies that allow for a better understanding of the underlying neural circuits. By combining neurostimulation with neuroimaging techniques such as PET and MRI, researchers can gain insights into how these therapies alter neural activity and connectivity within brain networks. This understanding is crucial for refining treatment protocols and tailoring interventions to individual patient profiles (Fujimoto et al., 2024) [4].

The recent development of closed-loop neurostimulation systems represents a significant advancement in the field. These systems utilize real-time feedback to adjust stimulation parameters based on biomarkers correlated with symptomatology, allowing for more personalized and effective treatment strategies. This approach addresses the inherent variability in psychiatric disorders, where symptoms may fluctuate over time (Sellers et al., 2024) [6].

In summary, neurostimulation treats psychiatric disorders by modulating key neurotransmitter systems, including serotonin, dopamine, and norepinephrine, to restore balance within dysfunctional neural circuits. The integration of neuroimaging and closed-loop systems further enhances the precision and efficacy of these interventions, paving the way for improved therapeutic outcomes in patients with resistant psychiatric conditions.

3.3 Neuroplasticity and Long-term Effects ​

Neurostimulation has emerged as a significant therapeutic approach for psychiatric disorders, primarily through its ability to modulate neuroplasticity—the brain's capacity to reorganize itself by forming new neural connections. This capacity is essential for cognitive and emotional adaptability and is often impaired in various psychiatric conditions.

Neuroplasticity is the dynamic structural and functional reorganization of the central nervous system in response to environmental and internal demands. It serves as a physiological basis for the adaptation of cognition and behavior, making it crucial for normal brain function. In psychiatric disorders, pathological alterations in neuroplasticity are increasingly recognized as a contributing factor to cognitive dysfunctions and symptomatology [29]. Non-invasive brain stimulation techniques (NIBS), such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), have shown the potential to induce and modulate neuroplasticity in humans. These techniques can alter pathological plasticity while promoting physiological plasticity, thereby reducing symptoms and enhancing rehabilitation [30].

The mechanisms by which neurostimulation exerts its effects on neuroplasticity involve several key processes. Firstly, NIBS techniques can induce long-term potentiation (LTP) and long-term depression (LTD), which are essential for synaptic plasticity. However, the phenomena of LTP and LTD alone do not fully account for the extensive changes observed following NIBS. Research indicates that a complex interplay of mechanisms is involved, including gene activation, de novo protein expression, morphological changes in neurons, and modifications in intrinsic firing properties and network dynamics due to altered inhibition and glial function [31].

Moreover, the therapeutic effects of NIBS are not merely short-lived; they can lead to enduring changes in synaptic excitability and network properties. This capacity for lasting change is critical for the treatment of chronic psychiatric disorders, where traditional therapies often fail to produce sustained benefits [32].

Recent advancements in neurostimulation technologies have also underscored the importance of understanding individual differences and brain states, which can significantly influence treatment outcomes. Personalizing NIBS protocols based on these factors may enhance therapeutic efficacy [33].

Furthermore, the combination of neurostimulation with other therapeutic modalities, such as psychotherapy, is gaining traction as a promising approach to amplify the effects of treatment. The integration of NIBS into psychotherapeutic frameworks aims to create a state of enhanced neuroplasticity, facilitating the uptake of cognitive and behavioral interventions and leading to improved long-term clinical outcomes [34].

In conclusion, neurostimulation treats psychiatric disorders by leveraging its capacity to induce and modulate neuroplasticity, which is fundamental for the reorganization of neural circuits. Through various mechanisms, including synaptic changes and gene expression alterations, neurostimulation fosters an environment conducive to recovery and adaptation in individuals with psychiatric conditions. The ongoing research in this field continues to reveal the complexities of neuroplasticity and its implications for therapeutic strategies, highlighting the potential for more effective treatments for psychiatric disorders.

4 Applications in Psychiatric Disorders ​

4.1 Treatment of Major Depressive Disorder ​

Neurostimulation has emerged as a significant therapeutic approach for various psychiatric disorders, particularly major depressive disorder (MDD). This treatment modality encompasses both invasive and non-invasive techniques, utilizing electrical stimulation to modulate neural circuits associated with mood regulation and emotional processing.

In the context of MDD, traditional pharmacotherapy has limitations, as a considerable proportion of patients do not respond adequately to standard antidepressant medications. Neurostimulation techniques offer alternative pathways for intervention. For instance, invasive methods such as deep brain stimulation (DBS) and vagus nerve stimulation (VNS) directly target specific neural structures, providing therapeutic effects by modulating dysfunctional neural circuitry associated with depression [3]. These techniques have been recognized as lifesaving for patients with treatment-resistant depression, where conventional treatments fail [35].

Non-invasive neurostimulation methods, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have gained traction as effective adjunctive treatments. TMS, which involves the application of magnetic fields to stimulate cortical neurons, has been shown to improve depressive symptoms by enhancing neuroplasticity and connectivity within the brain [36]. tDCS, on the other hand, employs weak electrical currents to modulate cortical excitability, demonstrating promise in altering the pathological state associated with depression [37]. These non-invasive techniques are advantageous as they are generally well-tolerated and can be administered in outpatient settings.

Moreover, the glutamatergic system plays a pivotal role in the pathophysiology of depression. The modulation of glutamatergic neurotransmission, particularly through the use of NMDA receptor antagonists like ketamine, has been highlighted as a rapid-acting treatment for depression [38]. This approach underscores the significance of targeting neuroplasticity in developing novel therapeutic strategies for MDD.

Neuroimaging studies have further elucidated the mechanisms by which neurostimulation exerts its effects, revealing changes in brain activity and connectivity that correlate with clinical improvement [39]. These insights enhance the understanding of the underlying neurobiological mechanisms and facilitate the optimization of neuromodulatory techniques.

In summary, neurostimulation therapies represent a promising avenue for treating major depressive disorder, particularly in cases where traditional pharmacotherapy is insufficient. The combination of invasive and non-invasive approaches, alongside the exploration of glutamatergic pathways, provides a comprehensive framework for developing effective treatment strategies aimed at alleviating the burden of depression. Continued research into the efficacy, safety, and underlying mechanisms of these therapies will be crucial in advancing their clinical application and improving patient outcomes.

4.2 Anxiety Disorders ​

Neurostimulation therapies have emerged as promising interventions for the treatment of psychiatric disorders, particularly anxiety disorders. These therapies, which include techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS), work by modulating neural circuitry associated with mood and anxiety regulation.

Anxiety disorders, which encompass conditions such as generalized anxiety disorder, panic disorder, and post-traumatic stress disorder (PTSD), often present significant treatment challenges. Traditional pharmacotherapy and psychotherapy can be effective; however, a substantial proportion of patients—estimated at 20% to 30%—remain symptomatic despite these interventions [40]. This gap in effective treatment has led to increased interest in neuromodulation techniques.

Research has demonstrated that neuromodulation therapies can significantly reduce anxiety symptoms across various anxiety disorders. A systematic review and meta-analysis indicated that interventions such as TMS and tDCS were associated with greater reductions in anxiety levels compared to control conditions, with a standardized mean difference of -0.56 [41]. Specifically, TMS has shown positive effects in treating generalized anxiety disorder and PTSD, with higher rates of clinical response and remission in active treatment conditions [41].

The underlying mechanisms by which neuromodulation therapies exert their effects are still being elucidated. It is hypothesized that these therapies modulate the activity of dysfunctional neural circuits involved in anxiety. For instance, TMS has been shown to target specific brain regions, such as the prefrontal cortex, which is crucial for emotion regulation [42]. By either exciting or inhibiting these areas, neuromodulation can help restore balance in the neural circuits implicated in anxiety.

Additionally, neuromodulation techniques may also influence neuroinflammatory processes associated with mood disorders. Studies have indicated that these therapies can attenuate neuroinflammation and reduce the release of pro-inflammatory factors, potentially contributing to mood improvement and symptom relief [25]. This aspect is particularly relevant given the growing recognition of the role of inflammation in the pathophysiology of anxiety and depression.

Combining neuromodulation with cognitive interventions has also shown promise. Research suggests that integrating non-invasive brain stimulation with cognitive rehabilitation strategies can enhance treatment outcomes for neuropsychiatric disorders [8]. The synergistic effects of these combination therapies may optimize the therapeutic benefits by further modulating ongoing neural activity in targeted networks.

In conclusion, neurostimulation therapies represent a novel and evolving approach to treating anxiety disorders. By targeting specific neural circuits and potentially modulating neuroinflammation, these techniques offer a complementary strategy to traditional treatments, addressing the unmet needs of patients who do not respond adequately to conventional therapies. Continued research is essential to refine these methods and better understand their mechanisms, ultimately enhancing their clinical efficacy in the management of anxiety disorders.

4.3 Obsessive-Compulsive Disorder (OCD) ​

Neurostimulation techniques have emerged as promising therapeutic options for psychiatric disorders, particularly for treatment-resistant conditions such as Obsessive-Compulsive Disorder (OCD). OCD is characterized by persistent, intrusive thoughts and ritualistic behaviors, leading to significant functional impairment. Traditional treatments, including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT), are effective for some patients, but approximately 40-60% of individuals experience inadequate responses, necessitating alternative approaches [43].

Deep Brain Stimulation (DBS) has gained attention as a viable treatment for severe, refractory OCD. This method involves the implantation of electrodes in specific brain regions to modulate neural circuits implicated in OCD. The ventral portion of the anterior limb of the internal capsule (ALIC) and the underlying ventral striatum have been established as effective targets for DBS, with FDA approval granted for this indication in 2009 [44]. Research indicates that DBS may alleviate OCD symptoms by modulating disturbances in the cortico-striato-thalamo-cortical (CSTC) circuitry, which is believed to underlie the disorder's pathophysiology [44].

Additionally, transcranial magnetic stimulation (TMS) has been explored as a non-invasive neurostimulation technique for OCD. TMS utilizes magnetic fields to induce electrical currents in targeted brain regions, influencing neuronal activity. Various studies have reported positive outcomes for patients with OCD, especially when targeting areas such as the supplementary motor area and the orbitofrontal cortex [45]. The application of continuous theta burst stimulation (cTBS), a specific TMS protocol, has shown promise in reducing obsessive-compulsive symptoms, even in cases resistant to pharmacotherapy [46].

Electroconvulsive therapy (ECT) is another neuromodulation strategy that has been utilized for severe psychiatric conditions, including OCD. While primarily associated with treatment-resistant depression, ECT's potential efficacy in OCD is being investigated, particularly for patients who have not responded to conventional treatments [45].

Neuroimaging advancements have significantly contributed to understanding the underlying neural circuits involved in OCD. This knowledge facilitates the identification of optimal stimulation targets, allowing for more personalized treatment approaches [44]. Furthermore, ongoing research aims to refine these techniques and explore new applications, enhancing their efficacy and accessibility for patients [43].

In summary, neurostimulation techniques, including DBS, TMS, and ECT, represent a transformative shift in the treatment landscape for OCD, particularly for those with treatment-resistant forms of the disorder. These methods leverage the modulation of dysfunctional neural circuits to alleviate symptoms, offering hope for improved outcomes in affected individuals. Continued research and clinical trials are essential to establish their efficacy, safety, and optimal application strategies in the context of OCD and other psychiatric disorders.

5 Efficacy and Safety Considerations ​

5.1 Clinical Outcomes and Effectiveness ​

Neurostimulation has emerged as a significant therapeutic modality for treating psychiatric disorders, particularly in cases where traditional treatments, such as medications and psychotherapy, have proven inadequate. The efficacy and safety of neurostimulation techniques are under continuous investigation, and recent findings provide valuable insights into clinical outcomes and effectiveness.

Neurostimulation therapies encompass a variety of techniques, including deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS). These methods involve the application of electrical or magnetic stimulation to specific brain regions to modulate neural activity. The rationale behind neurostimulation is based on the understanding that many psychiatric disorders are associated with aberrant activity in specific neural circuits and networks. By targeting these areas, neurostimulation aims to restore normal function and alleviate symptoms.

DBS, in particular, has shown promise in treating various psychiatric disorders, including depression and obsessive-compulsive disorder (OCD). Holtzheimer and Mayberg (2011) discussed that DBS has been supported by data demonstrating its safety and efficacy in movement disorders, and preliminary data suggest similar potential for psychiatric conditions [18]. Moreover, recent studies highlight that neurostimulation can provide significant relief for patients with treatment-resistant depression, where conventional therapies have failed [35].

In terms of efficacy, the use of closed-loop neurostimulation systems has been proposed as a more personalized approach to treatment. This technique utilizes biomarkers correlated with specific symptoms to deliver stimulation only during symptomatic periods, potentially increasing the effectiveness of therapy. Sellers et al. (2024) noted that the periodic nature of symptoms in psychiatric illnesses necessitates such tailored interventions, which could enhance therapeutic outcomes [6].

Safety considerations are paramount in the application of neurostimulation. The surgical placement of neurostimulation devices carries risks of neurologic injury and complications related to the intervention. Edwards et al. (2017) emphasized the need for ongoing evaluation of the safety profiles of these devices, as well as the importance of developing guidelines to minimize risks associated with their use [3]. The Neurostimulation Appropriateness Consensus Committee has worked to improve safety protocols, aiming to reduce the likelihood of severe neurological injuries during implantation [47].

Clinical outcomes associated with neurostimulation have shown a range of effectiveness. For instance, a review of various neurostimulation techniques highlighted the need for further understanding of their neurobiological mechanisms to optimize treatment for mood disorders [7]. Despite the promising results, the overall understanding of how these techniques exert their effects remains limited, necessitating further research to clarify their mechanisms and improve treatment protocols.

In conclusion, neurostimulation represents a burgeoning field in the treatment of psychiatric disorders, offering hope for patients who do not respond to conventional therapies. While evidence suggests that these techniques can be effective and generally safe, ongoing research is essential to fully elucidate their mechanisms, optimize treatment protocols, and ensure patient safety.

5.2 Side Effects and Risks ​

Neurostimulation has emerged as a promising treatment modality for psychiatric disorders, leveraging electrical stimulation to modulate neural activity in targeted brain regions. This approach encompasses various techniques, including deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS), each with unique mechanisms of action and clinical applications.

Efficacy of neurostimulation in treating psychiatric disorders is supported by numerous studies. For instance, DBS has been utilized in patients with treatment-resistant depression and obsessive-compulsive disorder, demonstrating significant improvements in symptoms for some individuals who have not responded to conventional therapies [48]. TMS and VNS have also shown efficacy in managing conditions such as major depressive disorder, with TMS being particularly noted for its safety profile and non-invasiveness [7].

The efficacy of these interventions is often enhanced when combined with cognitive interventions, as research suggests that integrating non-invasive brain stimulation with targeted cognitive strategies can optimize treatment outcomes [8]. The rationale is that neurostimulation can prime neural circuits for better engagement with cognitive therapies, potentially leading to more substantial and sustained improvements in symptoms [8].

However, the safety of neurostimulation therapies is a critical consideration. While many patients tolerate these treatments well, there are risks associated with each modality. For instance, DBS, while reversible and generally safe, carries risks such as infection, lead misplacement, and stimulation-related side effects, including mood changes or cognitive effects [48]. TMS is typically well-tolerated but can cause headaches, scalp discomfort, or, in rare cases, seizures [7]. VNS may lead to side effects such as voice changes, throat pain, or shortness of breath [7].

The side effects and risks associated with neurostimulation therapies can vary significantly among individuals, and the understanding of the underlying mechanisms remains incomplete. Current research indicates that the beneficial effects of neurostimulation may involve complex interactions within neural circuits, altering neurotransmitter systems and neural firing patterns [49]. As such, ongoing research is essential to elucidate these mechanisms and refine treatment protocols to maximize efficacy while minimizing adverse effects [7].

In summary, neurostimulation represents a valuable addition to the therapeutic arsenal for psychiatric disorders, with demonstrated efficacy and a generally favorable safety profile. However, careful consideration of potential side effects and ongoing research into the underlying mechanisms are crucial for optimizing treatment outcomes and patient safety.

5.3 Patient Acceptance and Adherence ​

Neurostimulation has emerged as a promising therapeutic modality for psychiatric disorders, providing relief to patients who may not respond adequately to conventional pharmacotherapy or psychotherapy. This treatment encompasses various techniques, including invasive and non-invasive methods, which apply electrical stimulation to modulate neural activity. A systematic review conducted on neuromodulation therapies, particularly for conditions like post-traumatic stress disorder (PTSD), highlights that many studies report favorable outcomes in alleviating both PTSD and depressive symptoms, suggesting a growing acceptance of these techniques in clinical practice [40].

Efficacy is a significant consideration in the application of neurostimulation for psychiatric disorders. Established invasive systems, such as deep brain stimulation (DBS), have been recognized for their ability to induce therapeutic neuromodulation in dysfunctional neural circuits. For instance, DBS has been noted to be one of the riskiest interventions, yet it also exhibits the highest efficacy in certain cases [50]. However, it is essential to acknowledge that the response to these treatments can be heterogeneous due to the complex nature of psychiatric disorders. Studies indicate that while some patients may experience significant benefits, others may show marginal or nonsignificant improvements, underscoring the necessity for personalized treatment approaches [40].

Safety is another critical aspect of neurostimulation. The implantation of neurostimulation devices carries risks of neurological injury and complications. The Neurostimulation Appropriateness Consensus Committee (NACC) has established safety guidelines aimed at reducing these risks, emphasizing the importance of best practices in the surgical placement of these devices [47]. The overall side effect profile of neuromodulation therapies tends to be low, with mostly mild adverse events reported, which is a positive factor for patient acceptance [40].

Patient acceptance and adherence to neurostimulation treatments are influenced by various factors, including perceived efficacy, safety, and the ethical considerations surrounding these interventions. A study assessing public perception of neuromodulation revealed that overall, participants had a positive view of these techniques, particularly after receiving information about their benefits and risks [51]. This highlights the importance of patient education in enhancing acceptance and adherence. Healthcare providers play a crucial role in informing patients about the safety and efficacy of neuromodulation, thereby promoting informed decision-making and adherence to treatment protocols [51].

Moreover, ethical concerns, such as patient autonomy and informed consent, are increasingly relevant in the discourse surrounding neurostimulation. The potential for changes in patient identity and personality post-intervention raises questions about the implications of these treatments on individual autonomy [50]. Thus, addressing these ethical dilemmas is vital for fostering trust and acceptance among patients considering neurostimulation as a treatment option.

In summary, neurostimulation offers a valuable alternative for treating psychiatric disorders, with established efficacy and a generally favorable safety profile. Patient acceptance and adherence are crucial for the success of these interventions, necessitating effective communication and education from healthcare providers to navigate the complexities associated with neuroethical considerations.

6 Future Directions and Challenges ​

6.1 Innovations in Neurostimulation Technology ​

Neurostimulation technologies have emerged as significant therapeutic options for treating psychiatric disorders, addressing the limitations of traditional pharmacological and psychotherapeutic approaches. These technologies encompass both invasive and noninvasive methods that apply electrical stimulation to modulate neural activity within specific brain circuits. Recent advancements in neurostimulation are fostering a deeper understanding of their mechanisms and expanding their clinical applications.

Neurostimulation therapies include various modalities such as deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS). These methods target specific neural structures, enabling therapeutic neuromodulation of dysfunctional circuitry associated with psychiatric disorders. For instance, VNS, which involves implanting a device that sends electrical pulses to the vagus nerve, has shown promise in treating medication-resistant depression by modulating brain activity without significant systemic side effects[52].

Innovations in neurostimulation technology are progressing towards closed-loop systems, which can dynamically adjust stimulation based on real-time neural activity. This approach aims to provide personalized therapy by delivering stimulation only during symptomatic periods, thereby improving treatment efficacy for heterogeneous psychiatric disorders[6]. The integration of biomarkers to guide stimulation parameters represents a significant advancement, potentially enhancing the precision of neurostimulation therapies.

Despite these advancements, challenges remain. The mechanisms underlying the therapeutic effects of neurostimulation are not fully understood, necessitating further research to elucidate how these therapies influence brain function and their relationship with various psychiatric conditions[4]. Additionally, ethical and clinical challenges related to device management, patient consent, and data ownership need to be addressed as closed-loop neurostimulation becomes more prevalent[9].

Future directions in neurostimulation research will likely focus on refining stimulation protocols, enhancing the safety and efficacy of these therapies, and exploring combination approaches that integrate neurostimulation with cognitive interventions[8]. This combination could optimize treatment outcomes by providing synergistic effects that address the multifaceted nature of psychiatric disorders[1].

In summary, neurostimulation technologies are revolutionizing the treatment landscape for psychiatric disorders, offering new hope for patients who do not respond adequately to conventional therapies. Continued innovation and research are essential to overcome existing challenges and unlock the full potential of these promising therapeutic modalities.

6.2 Research Gaps and Opportunities ​

Neurostimulation has emerged as a significant therapeutic approach for psychiatric disorders, leveraging various technologies to modulate neural activity and restore functional balance within brain circuits. The primary modalities include invasive techniques, such as deep brain stimulation (DBS), and non-invasive methods, like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). These interventions target specific neural pathways associated with mood regulation, cognitive processes, and other psychiatric symptoms.

The efficacy of neurostimulation therapies is underpinned by the neurobiological understanding of psychiatric disorders, which reveals that these conditions often stem from aberrant activity within neural circuits. As highlighted in recent literature, increasing insights into the neurobiology of psychiatric diseases have elucidated the complex interplay of various brain regions, necessitating personalized treatment strategies rather than a one-size-fits-all approach [6]. The application of closed-loop neurostimulation, where stimulation parameters are dynamically adjusted based on real-time feedback from biomarkers correlated with symptomatology, represents a promising avenue for enhancing therapeutic outcomes [6].

Despite the advancements, several challenges persist in the field of neurostimulation for psychiatric disorders. There remains a significant gap in understanding the precise mechanisms by which these therapies exert their effects. For instance, while the efficacy of neurostimulation has been demonstrated in various studies, the underlying neurobiological mechanisms are not fully elucidated, leading to uncertainties in optimizing treatment protocols [7]. Additionally, the heterogeneity of psychiatric disorders complicates the development of standardized treatment regimens, as symptoms can fluctuate widely among individuals [6].

Future directions in neurostimulation research are poised to focus on several key areas. Firstly, enhancing the efficacy and safety of existing modalities through the development of novel techniques and protocols is essential. This includes investigating the combination of neurostimulation with cognitive interventions, which has shown potential in improving treatment outcomes for disorders such as major depressive disorder and schizophrenia [8]. Furthermore, the exploration of new biomarker-driven approaches for closed-loop systems could lead to more tailored therapies that respond to the unique symptom profiles of patients [6].

Another critical area for future research involves addressing the ethical and economic considerations surrounding the widespread adoption of neurostimulation technologies. As these therapies become more integrated into clinical practice, ensuring equitable access and addressing the cost implications will be paramount [53]. Additionally, longitudinal studies are necessary to assess the long-term effects and safety of neurostimulation interventions, as well as their impact on overall quality of life in patients with psychiatric disorders [7].

In conclusion, while neurostimulation holds great promise for the treatment of psychiatric disorders, the field must navigate various challenges, including understanding the mechanisms of action, personalizing treatment approaches, and addressing ethical considerations. Continued research efforts will be vital in bridging the existing gaps and optimizing the therapeutic potential of neurostimulation for psychiatric conditions.

6.3 Ethical Considerations ​

Neurostimulation has emerged as a promising treatment modality for psychiatric disorders, addressing the limitations of traditional pharmacotherapy and psychotherapy. This approach encompasses both invasive and non-invasive techniques, such as deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS), which aim to modulate dysfunctional neural circuits involved in various psychiatric conditions.

Neurostimulation works by applying electrical or magnetic fields to specific brain regions, thereby altering neuronal activity and connectivity. This modulation can lead to symptom relief in treatment-resistant cases of depression, anxiety, schizophrenia, and obsessive-compulsive disorder (OCD) among others [3][4][28]. Recent advancements have focused on refining these techniques, with closed-loop systems gaining traction. Closed-loop neurostimulation utilizes real-time feedback from biomarkers to adjust stimulation parameters dynamically, thereby personalizing treatment and enhancing efficacy [6].

Despite the progress, several future directions and challenges remain. One significant challenge is the need for a deeper understanding of the underlying neurobiological mechanisms of neurostimulation. While these therapies have shown promise, the precise pathways through which they exert their effects are not fully elucidated [7]. Additionally, there is a pressing need for more robust clinical trials to establish optimal protocols and long-term outcomes for various neurostimulation techniques [2].

Ethical considerations also play a crucial role in the implementation of neurostimulation therapies. The introduction of closed-loop systems raises questions about data ownership, patient autonomy, and the potential for over-reliance on technology in mental health treatment [9]. Clinicians must navigate the complexities of informed consent, particularly when dealing with devices that continuously monitor brain activity. Furthermore, as neurostimulation becomes more integrated into clinical practice, ethical frameworks must evolve to address the implications of using such technologies, ensuring that they enhance patient care without compromising individual rights [5].

In conclusion, neurostimulation represents a frontier in the treatment of psychiatric disorders, with ongoing research aimed at refining techniques and understanding their mechanisms. However, the ethical implications of these advancements must be carefully considered to foster responsible and effective clinical applications.

7 Conclusion ​

Neurostimulation techniques have emerged as transformative tools in the treatment of psychiatric disorders, particularly for patients who are resistant to traditional pharmacological and psychotherapeutic interventions. This report synthesizes the current understanding of various neurostimulation modalities, including Transcranial Magnetic Stimulation (TMS), Deep Brain Stimulation (DBS), and Electroconvulsive Therapy (ECT), highlighting their mechanisms of action, efficacy, and safety profiles. Major findings indicate that these therapies can effectively modulate dysfunctional neural circuits, leading to significant symptom relief in conditions such as major depressive disorder, anxiety disorders, and obsessive-compulsive disorder. However, challenges remain, including the need for a deeper understanding of the underlying neurobiological mechanisms, the development of personalized treatment protocols, and the ethical implications of these interventions. Future research should focus on refining neurostimulation technologies, exploring combination therapies, and addressing ethical concerns to optimize treatment outcomes and enhance patient care. The continued evolution of neurostimulation holds great promise for improving the lives of individuals affected by psychiatric disorders, paving the way for more effective and personalized therapeutic strategies.

References ​

  • [1] Malek Bajbouj;Frank Padberg. A perfect match: noninvasive brain stimulation and psychotherapy.. European archives of psychiatry and clinical neuroscience(IF=3.7). 2014. PMID:25253645. DOI: 10.1007/s00406-014-0540-6.
  • [2] Susan K Conroy;Paul E Holtzheimer. Neuromodulation Strategies for the Treatment of Depression.. The American journal of psychiatry(IF=14.7). 2021. PMID:34855452. DOI: 10.1176/appi.ajp.2021.21101034.
  • [3] Christine A Edwards;Abbas Kouzani;Kendall H Lee;Erika K Ross. Neurostimulation Devices for the Treatment of Neurologic Disorders.. Mayo Clinic proceedings(IF=6.7). 2017. PMID:28870357. DOI: 10.1016/j.mayocp.2017.05.005.
  • [4] Satoka Fujimoto;Atsushi Fujimoto;Catherine Elorette;Ki Sueng Choi;Helen Mayberg;Brian Russ;Peter Rudebeck. What can neuroimaging of neuromodulation reveal about the basis of circuit therapies for psychiatry?. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2024. PMID:39198580. DOI: 10.1038/s41386-024-01976-2.
  • [5] Panayiota G Michalopoulou;Kyrillos M Meshreky;Zoe Hommerich;Sukhi S Shergill. Neuromodulation and neural networks in psychiatric disorders: current status and emerging prospects.. Psychological medicine(IF=5.5). 2025. PMID:40999798. DOI: 10.1017/S003329172510158X.
  • [6] Kristin K Sellers;Joshua L Cohen;Ankit N Khambhati;Joline M Fan;A Moses Lee;Edward F Chang;Andrew D Krystal. Closed-loop neurostimulation for the treatment of psychiatric disorders.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2024. PMID:37369777. DOI: 10.1038/s41386-023-01631-2.
  • [7] Masoud Afshari;Catherine Belzung;Solal Bloch. Neurostimulation as a treatment for mood disorders in patients: recent findings.. Current opinion in psychiatry(IF=4.9). 2023. PMID:36449728. DOI: 10.1097/YCO.0000000000000835.
  • [8] Aakash V Sathappan;Bruce M Luber;Sarah H Lisanby. The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions.. Progress in neuro-psychopharmacology & biological psychiatry(IF=3.9). 2019. PMID:30312634. DOI: 10.1016/j.pnpbp.2018.10.006.
  • [9] Manu Hegde;Winston Chiong;Vikram R Rao. New Ethical and Clinical Challenges in "Closed-Loop" Neuromodulation.. Neurology(IF=8.5). 2021. PMID:33727407. DOI: 10.1212/WNL.0000000000011834.
  • [10] Kneginja Richter;Stefanie Kellner;Christiane Licht. rTMS in mental health disorders.. Frontiers in network physiology(IF=3.0). 2023. PMID:37577037. DOI: 10.3389/fnetp.2023.943223.
  • [11] Tal Burt;Sarah H Lisanby;Harold A Sackeim. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis.. The international journal of neuropsychopharmacology(IF=3.7). 2002. PMID:12057034. DOI: 10.1017/S1461145702002791.
  • [12] Fabio Ferrarelli;Mary L Phillips. Examining and Modulating Neural Circuits in Psychiatric Disorders With Transcranial Magnetic Stimulation and Electroencephalography: Present Practices and Future Developments.. The American journal of psychiatry(IF=14.7). 2021. PMID:33653120. DOI: 10.1176/appi.ajp.2020.20071050.
  • [13] H Magnus Haraldsson;Fabio Ferrarelli;Ned H Kalin;Giulio Tononi. Transcranial Magnetic Stimulation in the investigation and treatment of schizophrenia: a review.. Schizophrenia research(IF=3.5). 2004. PMID:15374567. DOI: 10.1016/j.schres.2003.10.006.
  • [14] Shixie Jiang;Linda L Carpenter;Huabei Jiang. Optical neuroimaging: advancing transcranial magnetic stimulation treatments of psychiatric disorders.. Visual computing for industry, biomedicine, and art(IF=6.0). 2022. PMID:36071259. DOI: 10.1186/s42492-022-00119-y.
  • [15] Svjetlana Miocinovic;Suvarchala Somayajula;Shilpa Chitnis;Jerrold L Vitek. History, applications, and mechanisms of deep brain stimulation.. JAMA neurology(IF=21.3). 2013. PMID:23407652. DOI: 10.1001/2013.jamaneurol.45.
  • [16] Rollin Hu;Emad Eskandar;Ziv Williams. Role of deep brain stimulation in modulating memory formation and recall.. Neurosurgical focus(IF=3.0). 2009. PMID:19569891. DOI: 10.3171/2009.4.FOCUS0975.
  • [17] Jens Kuhn;Theo O J Gründler;Doris Lenartz;Volker Sturm;Joachim Klosterkötter;Wolfgang Huff. Deep brain stimulation for psychiatric disorders.. Deutsches Arzteblatt international(IF=7.1). 2010. PMID:20221269. DOI: 10.3238/arztebl.2010.0105.
  • [18] Paul E Holtzheimer;Helen S Mayberg. Deep brain stimulation for psychiatric disorders.. Annual review of neuroscience(IF=13.2). 2011. PMID:21692660. DOI: 10.1146/annurev-neuro-061010-113638.
  • [19] Ilse Graat;Martijn Figee;Damiaan Denys. The application of deep brain stimulation in the treatment of psychiatric disorders.. International review of psychiatry (Abingdon, England)(IF=3.4). 2017. PMID:28523977. DOI: 10.1080/09540261.2017.1282439.
  • [20] Klaus J Wagner;Oliver Möllenberg;Michael Rentrop;Christian Werner;Eberhard F Kochs. Guide to anaesthetic selection for electroconvulsive therapy.. CNS drugs(IF=7.4). 2005. PMID:16142990. DOI: 10.2165/00023210-200519090-00002.
  • [21] Ermin Fetahovic;Vladimir Janjic;Maja Muric;Nemanja Jovicic;Branimir Radmanovic;Gvozden Rosic;Dragica Selakovic;Milos Filipovic;Nemanja Muric. Neurobiological Mechanisms of Electroconvulsive Therapy: Molecular Perspectives of Brain Stimulation.. International journal of molecular sciences(IF=4.9). 2025. PMID:40565369. DOI: 10.3390/ijms26125905.
  • [22] Amber M Leaver;Randall Espinoza;Benjamin Wade;Katherine L Narr. Parsing the Network Mechanisms of Electroconvulsive Therapy.. Biological psychiatry(IF=9.0). 2022. PMID:35120710. DOI: 10.1016/j.biopsych.2021.11.016.
  • [23] Raguraman Janakiraman;Keith Wildgoose;Kalyan Seelam. ECT associated musical hallucinations in an elderly patient: a case report.. Annals of general psychiatry(IF=3.1). 2006. PMID:16889667. DOI: 10.1186/1744-859X-5-10.
  • [24] . Consensus conference. Electroconvulsive therapy.. JAMA(IF=55.0). 1985. PMID:4046138. DOI: .
  • [25] Bingqi Guo;Mengyao Zhang;Wensi Hao;Yuping Wang;Tingting Zhang;Chunyan Liu. Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression.. Translational psychiatry(IF=6.2). 2023. PMID:36624089. DOI: 10.1038/s41398-022-02297-y.
  • [26] Meaghan Creed. Current and emerging neuromodulation therapies for addiction: insight from pre-clinical studies.. Current opinion in neurobiology(IF=5.2). 2018. PMID:29524847. DOI: 10.1016/j.conb.2018.02.015.
  • [27] J M Gorman;G Sullivan. Noradrenergic approaches to antidepressant therapy.. The Journal of clinical psychiatry(IF=4.6). 2000. PMID:10703758. DOI: .
  • [28] Anand K Pandurangi;Catherine Fernicola-Bledowski;Josef Bledowski. Brain stimulation therapies for psychiatric disorders: The first decade of the new millennium--A review.. Asian journal of psychiatry(IF=4.5). 2012. PMID:26878940. DOI: 10.1016/j.ajp.2011.11.009.
  • [29] Min-Fang Kuo;Po-See Chen;Michael A Nitsche. The application of tDCS for the treatment of psychiatric diseases.. International review of psychiatry (Abingdon, England)(IF=3.4). 2017. PMID:28523976. DOI: 10.1080/09540261.2017.1286299.
  • [30] Min-Fang Kuo;Walter Paulus;Michael A Nitsche. Therapeutic effects of non-invasive brain stimulation with direct currents (tDCS) in neuropsychiatric diseases.. NeuroImage(IF=4.5). 2014. PMID:23747962. DOI: .
  • [31] G Cirillo;G Di Pino;F Capone;F Ranieri;L Florio;V Todisco;G Tedeschi;K Funke;V Di Lazzaro. Neurobiological after-effects of non-invasive brain stimulation.. Brain stimulation(IF=8.4). 2017. PMID:27931886. DOI: 10.1016/j.brs.2016.11.009.
  • [32] Joshua Hendrikse;Aaron Kandola;James Coxon;Nigel Rogasch;Murat Yücel. Combining aerobic exercise and repetitive transcranial magnetic stimulation to improve brain function in health and disease.. Neuroscience and biobehavioral reviews(IF=7.9). 2017. PMID:28951250. DOI: 10.1016/j.neubiorev.2017.09.023.
  • [33] Amitabh Bhattacharya;Ghazaleh Darmani;Kaviraja Udupa;Jean-François Nankoo;Mandy Yi Rong Ding;Robert Chen. Induction of plasticity and metaplasticity using noninvasive brain stimulation.. Trends in neurosciences(IF=15.1). 2025. PMID:40813159. DOI: 10.1016/j.tins.2025.07.009.
  • [34] Daniele Saccenti;Leonor J Romero Lauro;Sofia A Crespi;Andrea S Moro;Alessandra Vergallito;Regina Gregori Grgič;Novella Pretti;Jacopo Lamanna;Mattia Ferro. Boosting Psychotherapy With Noninvasive Brain Stimulation: The Whys and Wherefores of Modulating Neural Plasticity to Promote Therapeutic Change.. Neural plasticity(IF=3.7). 2024. PMID:39723244. DOI: 10.1155/np/7853199.
  • [35] Linda L Carpenter. Neurostimulation in resistant depression.. Journal of psychopharmacology (Oxford, England)(IF=5.5). 2006. PMID:16644770. DOI: 10.1177/1359786806064327.
  • [36] Mohamed Adil Shah Khoodoruth;Maria Anayali Estudillo-Guerra;Kevin Pacheco-Barrios;Azan Nyundo;Gina Chapa-Koloffon;Sami Ouanes. Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization.. Frontiers in psychiatry(IF=3.2). 2022. PMID:35492692. DOI: 10.3389/fpsyt.2022.886918.
  • [37] Michael A Nitsche;Paulo S Boggio;Felipe Fregni;Alvaro Pascual-Leone. Treatment of depression with transcranial direct current stimulation (tDCS): a review.. Experimental neurology(IF=4.2). 2009. PMID:19348793. DOI: 10.1016/j.expneurol.2009.03.038.
  • [38] Yu-Jhen Huang;Hsien-Yuan Lane;Chieh-Hsin Lin. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.. Neural plasticity(IF=3.7). 2017. PMID:28491480. DOI: 10.1155/2017/4605971.
  • [39] Ning Xu;Yue He;Yong-Nan Wei;Lu Bai;Long Wang. Possible antidepressant mechanism of acupuncture: targeting neuroplasticity.. Frontiers in neuroscience(IF=3.2). 2025. PMID:40018358. DOI: 10.3389/fnins.2025.1512073.
  • [40] Flavia Venetucci Gouveia;Benjamin Davidson;Ying Meng;Darryl Christopher Gidyk;Jennifer S Rabin;Enoch Ng;Agessandro Abrahao;Nir Lipsman;Peter Giacobbe;Clement Hamani. Treating Post-traumatic Stress Disorder with Neuromodulation Therapies: Transcranial Magnetic Stimulation, Transcranial Direct Current Stimulation, and Deep Brain Stimulation.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(IF=6.9). 2020. PMID:32468235. DOI: 10.1007/s13311-020-00871-0.
  • [41] Florian Gay;Allison Singier;Bruno Aouizerate;Francesco Salvo;Thomas C M Bienvenu. Neuromodulation Treatments of Pathological Anxiety in Anxiety Disorders, Stressor-Related Disorders, and Major Depressive Disorder: A Dimensional Systematic Review and Meta-Analysis.. Frontiers in psychiatry(IF=3.2). 2022. PMID:35845453. DOI: 10.3389/fpsyt.2022.910897.
  • [42] C M Vicario;Mohammad Ali Salehinejad;K Felmingham;G Martino;M A Nitsche. A systematic review on the therapeutic effectiveness of non-invasive brain stimulation for the treatment of anxiety disorders.. Neuroscience and biobehavioral reviews(IF=7.9). 2019. PMID:30543906. DOI: 10.1016/j.neubiorev.2018.12.012.
  • [43] Nicola Acevedo;David Castle;Susan Rossell. The promise and challenges of transcranial magnetic stimulation and deep brain stimulation as therapeutic options for obsessive-compulsive disorder.. Expert review of neurotherapeutics(IF=3.4). 2024. PMID:38247445. DOI: 10.1080/14737175.2024.2306875.
  • [44] Patrick J Karas;Sungho Lee;Joohi Jimenez-Shahed;Wayne K Goodman;Ashwin Viswanathan;Sameer A Sheth. Deep Brain Stimulation for Obsessive Compulsive Disorder: Evolution of Surgical Stimulation Target Parallels Changing Model of Dysfunctional Brain Circuits.. Frontiers in neuroscience(IF=3.2). 2018. PMID:30670945. DOI: 10.3389/fnins.2018.00998.
  • [45] Kyle A B Lapidus;Emily R Stern;Heather A Berlin;Wayne K Goodman. Neuromodulation for obsessive-compulsive disorder.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics(IF=6.9). 2014. PMID:24981434. DOI: 10.1007/s13311-014-0287-9.
  • [46] Yoshihiro Noda;Kyoshiro Fujii;Fumi Tokura;Shinichiro Nakajima;Ryosuke Kitahata. A Case Series of Continuous Theta Burst Stimulation Treatment for the Supplementary Motor Area Twice a Day in Patients with Obsessive-Compulsive Disorder: A Real World TMS Registry Study in Japan.. Journal of personalized medicine(IF=3.0). 2023. PMID:37241045. DOI: 10.3390/jpm13050875.
  • [47] Timothy R Deer;Tim J Lamer;Jason E Pope;Steven M Falowski;David A Provenzano;Konstantin Slavin;Stanley Golovac;Jeffrey Arle;Joshua M Rosenow;Kayode Williams;Porter McRoberts;Samer Narouze;Sam Eldabe;Shivanand P Lad;Jose A De Andrés;Eric Buchser;Philippe Rigoard;Robert M Levy;Brian Simpson;Nagy Mekhail. The Neurostimulation Appropriateness Consensus Committee (NACC) Safety Guidelines for the Reduction of Severe Neurological Injury.. Neuromodulation : journal of the International Neuromodulation Society(IF=3.5). 2017. PMID:28042918. DOI: 10.1111/ner.12564.
  • [48] B Nuttin;L Gabriëls;P Cosyns;J Gybels. Electrical stimulation of the brain for psychiatric disorders.. CNS spectrums(IF=4.1). 2000. PMID:18188147. DOI: 10.1017/s1092852900021908.
  • [49] Jing-Yu Chang. Brain stimulation for neurological and psychiatric disorders, current status and future direction.. The Journal of pharmacology and experimental therapeutics(IF=3.8). 2004. PMID:14730004. DOI: 10.1124/jpet.103.049718.
  • [50] Jonathan Shaw;Sagar Pyreddy;Colton Rosendahl;Charles Lai;Emily Ton;Rustin Carter. Current Neuroethical Perspectives on Deep Brain Stimulation and Neuromodulation for Neuropsychiatric Disorders: A Scoping Review of the Past 10 Years.. Diseases (Basel, Switzerland)(IF=3.0). 2025. PMID:40863235. DOI: 10.3390/diseases13080262.
  • [51] Cyril Atkinson-Clement;Andrea Junor;Marcus Kaiser. Neuromodulation perception by the general public.. Scientific reports(IF=3.9). 2025. PMID:39955336. DOI: 10.1038/s41598-025-89437-8.
  • [52] Mark S George;Ziad Nahas;Jeffrey J Borckardt;Berry Anderson;Carol Burns;Samet Kose;E Baron Short. Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders.. Expert review of neurotherapeutics(IF=3.4). 2007. PMID:17187498. DOI: 10.1586/14737175.7.1.63.
  • [53] Tim Denison;Martha J Morrell. Neuromodulation in 2035: The Neurology Future Forecasting Series.. Neurology(IF=8.5). 2022. PMID:35263267. DOI: 10.1212/WNL.0000000000013061.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Neurostimulation · Psychiatric Disorders · Therapeutic Approaches · Neurobiology · Non-invasive Techniques

© 2025 MaltSci